Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases

US Grant for Foamix's Saccharide Foam Patent - Topical "Sweet Foam" Products for Wound & Burn Therapy

Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures

Dermatology co Foamix teams with Switzerland's Galderma

Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne


 
Featured Dermatological Products

  • BetMetFoam™Emollient & BetMetFoam™Oily
    • Alcohol-Free Betamethasone valerate 0.12% in Foamix's proprietary Emollient Foam and Oily Foam bases. Easy to apply onto sensitive skin and mucosal areas. Most suitable to treat superficial inflammation, such as psoriasis and atopic dermatitis.
         
  • TerbiFoam™
    • Terbinafine in Foamix's Emollient Foam base. An easy-to-apply product for the treatment of dermal mycoses, e.g., athlete's foot and other dermatophite infections.
         
  • AcycloFoam™
    • Acyclovir in Foamix' Emollient Foam base. An easy-to-apply product for the treatment of sensitive skin and mucosal areas. Most suitable to treat genital and labial herpes.
         
  • DicloFoam™
    • Diclofenac 1% in Penetrating Emollient Foam base. A superior product to treat ostheoarthritis joint & back pain. Diclofenac 3% in Emollient Foam base. A superior product to treat actinic keratoses.
         
  • PerFoam™
    • Permethrin 1% and 5% in Foamix's Emollient Foam base. Ideal for application to the scalp and pubic area. Most suitable to treat head lice (1%) pubic lice and scabies (5%).
         
  • DEETFoam™
    • A unique Diethyl Toluamide (DEET) 25% foam. Easily spread over large body areas, for long lasting protection from insect bite.
         
  • LactiFoam™
    • Moisturizing, easily spreadable and highly absorbable Ammonium lactate 12% emollient foam. This delicate alcohol-free foam product is ideal in the treatment of dry, scaly skin, including ichthyosis vulgaris.
         
  • Urea Foam™
    • Moisturizing, easily spreadable and highly absorbable 10%, 20% and 40% Urea emollient foam. Most suitable in the treatment of dry, scaly skin, including ichthyosis vulgaris and xerosis.
       
  • AtopiFoam™
    • AtopiFoam™ is a novel alcohol-free emollient foam especially designed to treat the symptoms of atopic dermatitis. It protects the injured skin from further irritation, restores skin moisture level, and exerts a potent anti-inflammatory action.